Contineum Therapeutics (CTNM) EBITDA Margin (2023)
Contineum Therapeutics' EBITDA Margin history spans 1 years, with the latest figure at 83.02% for Q2 2023.
- Quarterly EBITDA Margin changed N/A to 83.02% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 63.02% through Jun 2024, changed N/A year-over-year, with the annual reading at 45.81% for FY2023, N/A changed from the prior year.
- EBITDA Margin came in at 83.02% for Q2 2023.
- In the past five years, EBITDA Margin ranged from a high of 83.02% in Q2 2023 to a low of 83.02% in Q2 2023.